For instance, PANDAR exerts regulatory control over the transcription of the CDKN1A gene by competitively binding with the p53 protein at the CDKN1A promoter in a p53-dependent manner, thereby augmenting the resistance of gastric cancer cell lines to oxaliplatin [86]. This evidence concerns the gene CDKN1A and gastric cancer.